vs
Phoenix Education Partners, Inc.（PXED）与ROGERS CORP（ROG）财务数据对比。点击上方公司名可切换其他公司
Phoenix Education Partners, Inc.的季度营收约是ROGERS CORP的1.1倍（$222.5M vs $200.5M），Phoenix Education Partners, Inc.净利率更高（4.8% vs 2.2%，领先2.6%），Phoenix Education Partners, Inc.自由现金流更多（$43.5M vs $1.1M）
凤凰城大学是总部位于美国亚利桑那州凤凰城的私立营利性大学，由凤凰城教育合伙公司持有，1976年成立，可颁发证书及副学士、学士、硕士、博士多个层级的学位。该校获高等教育委员会官方认证，不少本科项目实行开放入学政策。
罗杰斯公司是一家专注于特种工程材料研发生产的企业，总部位于美国亚利桑那州钱德勒市，其产品广泛应用于先进电子、移动通信、清洁能源、航空航天等多个高科技领域，为全球客户提供高性能材料解决方案。
PXED vs ROG — 直观对比
营收规模更大
PXED
是对方的1.1倍
$200.5M
净利率更高
PXED
高出2.6%
2.2%
自由现金流更多
PXED
多$42.4M
$1.1M
损益表 — Q2 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $222.5M | $200.5M |
| 净利润 | $10.8M | $4.5M |
| 毛利率 | — | 32.2% |
| 营业利润率 | 6.3% | — |
| 净利率 | 4.8% | 2.2% |
| 营收同比 | — | 5.2% |
| 净利润同比 | — | 421.4% |
| 每股收益（稀释后） | $0.28 | $0.25 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PXEDROG
| Q1 26 | $222.5M | $200.5M | ||
| Q4 25 | $262.0M | $201.5M | ||
| Q3 25 | — | $216.0M | ||
| Q2 25 | — | $202.8M | ||
| Q1 25 | — | $190.5M | ||
| Q4 24 | — | $192.2M | ||
| Q3 24 | — | $210.3M | ||
| Q2 24 | — | $214.2M |
净利润PXEDROG
| Q1 26 | $10.8M | $4.5M | ||
| Q4 25 | $15.5M | $4.6M | ||
| Q3 25 | — | $8.6M | ||
| Q2 25 | — | $-73.6M | ||
| Q1 25 | — | $-1.4M | ||
| Q4 24 | — | $-500.0K | ||
| Q3 24 | — | $10.7M | ||
| Q2 24 | — | $8.1M |
毛利率PXEDROG
| Q1 26 | — | 32.2% | ||
| Q4 25 | — | 31.5% | ||
| Q3 25 | — | 33.5% | ||
| Q2 25 | — | 31.6% | ||
| Q1 25 | — | 29.9% | ||
| Q4 24 | — | 32.1% | ||
| Q3 24 | — | 35.2% | ||
| Q2 24 | — | 34.1% |
营业利润率PXEDROG
| Q1 26 | 6.3% | — | ||
| Q4 25 | 9.8% | 3.5% | ||
| Q3 25 | — | 7.3% | ||
| Q2 25 | — | -33.3% | ||
| Q1 25 | — | -0.2% | ||
| Q4 24 | — | -6.6% | ||
| Q3 24 | — | 6.9% | ||
| Q2 24 | — | 5.3% |
净利率PXEDROG
| Q1 26 | 4.8% | 2.2% | ||
| Q4 25 | 5.9% | 2.3% | ||
| Q3 25 | — | 4.0% | ||
| Q2 25 | — | -36.3% | ||
| Q1 25 | — | -0.7% | ||
| Q4 24 | — | -0.3% | ||
| Q3 24 | — | 5.1% | ||
| Q2 24 | — | 3.8% |
每股收益（稀释后）PXEDROG
| Q1 26 | $0.28 | $0.25 | ||
| Q4 25 | $0.40 | $0.20 | ||
| Q3 25 | — | $0.48 | ||
| Q2 25 | — | $-4.00 | ||
| Q1 25 | — | $-0.08 | ||
| Q4 24 | — | $-0.04 | ||
| Q3 24 | — | $0.58 | ||
| Q2 24 | — | $0.44 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $201.4M | $195.8M |
| 总债务越低越好 | $58.8M | — |
| 股东权益账面价值 | $291.1M | $1.2B |
| 总资产 | $546.4M | $1.4B |
| 负债/权益比越低杠杆越低 | 0.20× | — |
8季度趋势，按日历期对齐
现金及短期投资PXEDROG
| Q1 26 | $201.4M | $195.8M | ||
| Q4 25 | $163.5M | $197.0M | ||
| Q3 25 | — | $167.8M | ||
| Q2 25 | — | $157.2M | ||
| Q1 25 | — | $175.6M | ||
| Q4 24 | — | $159.8M | ||
| Q3 24 | — | $146.4M | ||
| Q2 24 | — | $119.9M |
总债务PXEDROG
| Q1 26 | $58.8M | — | ||
| Q4 25 | $61.6M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益PXEDROG
| Q1 26 | $291.1M | $1.2B | ||
| Q4 25 | $280.4M | $1.2B | ||
| Q3 25 | — | $1.2B | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | — | $1.3B | ||
| Q4 24 | — | $1.3B | ||
| Q3 24 | — | $1.3B | ||
| Q2 24 | — | $1.3B |
总资产PXEDROG
| Q1 26 | $546.4M | $1.4B | ||
| Q4 25 | $549.6M | $1.4B | ||
| Q3 25 | — | $1.4B | ||
| Q2 25 | — | $1.5B | ||
| Q1 25 | — | $1.5B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | — | $1.5B | ||
| Q2 24 | — | $1.5B |
负债/权益比PXEDROG
| Q1 26 | 0.20× | — | ||
| Q4 25 | 0.22× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $48.9M | $5.8M |
| 自由现金流经营现金流 - 资本支出 | $43.5M | $1.1M |
| 自由现金流率自由现金流/营收 | 19.6% | 0.5% |
| 资本支出强度资本支出/营收 | 2.4% | 2.3% |
| 现金转化率经营现金流/净利润 | 4.53× | 1.29× |
| 过去12个月自由现金流最近4个季度 | — | $70.1M |
8季度趋势，按日历期对齐
经营现金流PXEDROG
| Q1 26 | $48.9M | $5.8M | ||
| Q4 25 | $31.1M | $46.9M | ||
| Q3 25 | — | $28.9M | ||
| Q2 25 | — | $13.7M | ||
| Q1 25 | — | $11.7M | ||
| Q4 24 | — | $33.7M | ||
| Q3 24 | — | $42.4M | ||
| Q2 24 | — | $22.9M |
自由现金流PXEDROG
| Q1 26 | $43.5M | $1.1M | ||
| Q4 25 | $26.4M | $42.2M | ||
| Q3 25 | — | $21.2M | ||
| Q2 25 | — | $5.6M | ||
| Q1 25 | — | $2.1M | ||
| Q4 24 | — | $18.3M | ||
| Q3 24 | — | $25.2M | ||
| Q2 24 | — | $8.8M |
自由现金流率PXEDROG
| Q1 26 | 19.6% | 0.5% | ||
| Q4 25 | 10.1% | 20.9% | ||
| Q3 25 | — | 9.8% | ||
| Q2 25 | — | 2.8% | ||
| Q1 25 | — | 1.1% | ||
| Q4 24 | — | 9.5% | ||
| Q3 24 | — | 12.0% | ||
| Q2 24 | — | 4.1% |
资本支出强度PXEDROG
| Q1 26 | 2.4% | 2.3% | ||
| Q4 25 | 1.8% | 2.3% | ||
| Q3 25 | — | 3.6% | ||
| Q2 25 | — | 4.0% | ||
| Q1 25 | — | 5.0% | ||
| Q4 24 | — | 8.0% | ||
| Q3 24 | — | 8.2% | ||
| Q2 24 | — | 6.6% |
现金转化率PXEDROG
| Q1 26 | 4.53× | 1.29× | ||
| Q4 25 | 2.01× | 10.20× | ||
| Q3 25 | — | 3.36× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 3.96× | ||
| Q2 24 | — | 2.83× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
